
Publication
NRF Insights on the DFSA’s Business Plan for 2025-26
On 4 February 2025, the Dubai Financial Services Authority (the DFSA) published its Business Plan for 2025-2026 (the Business Plan).
As the COVID pandemic lumbers on to its third year, there continues to be global disparities in access to the tools (i.e., vaccines and therapeutics) necessary to combat the pandemic.
A core reason behind this disparity is the developing world’s lack of access to the intellectual property (and technical know-how) required to manufacture these vital vaccines and therapeutics. In 2021, the United States announced that it would support the temporary waiver of intellectual property protections for COVID-19 vaccines under the Trade Related Aspects of Intellectual Property Rights (“TRIPS”) Agreement.
This article explores the current controversy around the waiver of intellectual property rights for COVID-19 vaccines and therapeutics and their implications for life sciences companies.
Read the full article from The Life Sciences Lawyer Magazine, "Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies."
Publication
On 4 February 2025, the Dubai Financial Services Authority (the DFSA) published its Business Plan for 2025-2026 (the Business Plan).
Publication
Acting on one of the priorities laid out in President von der Leyen’s Mission Letter to Commissioner McGrath, the European Commission (EC) has published a communication on an EU toolbox for safe and sustainable e-commerce (the Communication).
Publication
The construction and infrastructure sectors are booming in the Middle East region, driven by economic diversification and energy transition goals. It is more important than ever to carefully mitigate and manage risk and resolve disputes effectively, should they arise.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025